Synopsis: BofA bought a 0.52 percent stake in an Ashish Kacholia-held company, highlighting rising institutional interest amid strong returns and improving financial performance.
The share of this company, which is engaged in the manufacture and sale of injection moulded precision plastic components, sub-assemblies for various requirements of Original Equipment Manufacturers, came into focus after a global institution bought a stake in it.
With a market capitalization of Rs 12,077 crore, Shaily Engineering Plastics Ltd’s share closed at Rs 2,627 per share, up by 0.95 percent from its previous day’s close. The share of this company has given a return of 505 percent in the last four years.
What Happened
As of March 2026, BofA held around a 1.13 percent stake in the company. This reflects an existing institutional position ahead of further accumulation, indicating continued investor presence in the counter.
On April 24, 2026, BofA Securities Europe bought 236,911 shares at Rs 2419.42 per share, adding about 0.52 percent stake. This took their total holding to nearly 1.65 percent, showing increased institutional interest and participation.
Also, Foreign Institutional Investors (FIIs) have significantly increased their stake from 2.04 percent in June 2024 to 16.73 percent as of March 2026, reflecting strong institutional confidence and sustained accumulation. Additionally, ace investor Ashish Kacholia holds a 3.22 percent stake, further reinforcing the company’s credibility and long-term investment appeal.
Shareholding pattern: As of Q4 FY26, the shareholding pattern shows a clear YoY shift, with FII stake rising to 16.73 percent from 7.38 percent. Promoter holding dipped slightly from 43.72 percent to 43.39 percent, while DII stake declined to 10.61 percent from 13.73 percent. Public holding fell to 29.27 percent from 35.17 percent.
About the Company
Shaily Engineering Plastics is an Indian company that makes small, highly accurate plastic parts using moulding machines. These parts are mainly used in medical devices, packaged consumer goods, and home products, and the company also helps in designing and producing them for large global companies.
Segment-wise Revenue Breakup:As of Q3 FY26, total revenue increased to 250.5 from 197.6 in Q3 FY25, reflecting a growth of 27 percent year on year. The overall performance was primarily supported by strong traction in non-consumer segments, which offset the decline in the core consumer business.
Segment-wise, Consumer revenue declined from 141.3 in Q3 FY25 to 122.8 in Q3 FY26, down 13 percent year on year, indicating softness in the base segment. In contrast, Healthcare reported a sharp rise from 43.7 to 104.3, growing 139 percent year on year, emerging as the key growth driver. Industrial revenue also increased from 12.5 to 23.4, up 87 percent year on year, reflecting broad-based expansion in this segment.
As of Q3 FY26, the company continues to strengthen its leadership in GLP-1 drug delivery devices, supported by rising global demand for pen and auto-injectors used in advanced therapies. Alongside this, the business maintains a strong international footprint, with exports contributing around 71 percent of total revenue, reflecting a well-diversified revenue base and sustained global growth momentum.
Financial Highlights: Revenue from operations stood at Rs 236 crore in Q3 FY26, up from Rs 186 crore in Q3 FY25, reflecting a YoY growth of around 27 percent. The company also reported a strong improvement in operating margin, which expanded to 27 percent in Q3 FY26 from 20 percent in the same period last year.
Net profit doubled to Rs 36 crore in Q3 FY26 from Rs 18 crore in Q3 FY25, marking a 100 percent YoY increase. EPS also showed sharp growth, rising to Rs 7.76 per share from Rs 2.93 per share, up nearly 165 percent YoY, supported by stronger profitability and improved operating performance.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
